A Randomized Phase III Study of Standard Treatment +/- Enoxaparin in Small Cell Lung Cancer
Chemotherapy will be given in accordance with local or regional guidelines but shall include
a platinum drug + any topoisomerase inhibitor. Within these limits the study will accept
different local variants as long as each centre remains consistent to its declared standard
chemotherapy regimen. The recommended regimen is carboplatin or cisplatin plus etoposide q3
weeks for 4 cycles but up to 6 cycles is allowed. Local dosages and dose reduction schedules
will be used.
Interventional
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Significant increase of overall survival
At follow up 1 year after treatment
Yes
Lars Ek, MD
Principal Investigator
University Hospital, Lund
Sweden: Medical Products Agency
EudraCT number 2007-006033-14
NCT00717938
June 2008
December 2013
Name | Location |
---|